Rigel Pharmaceuticals, Inc. RIGL
Set alert
51.31 USD -0.14 -0.27%
At close · Oct 30
49.65 -1.66 -3.24%
After hours · Oct 30, 6:58 PM ET
50.67 Day range 52.61
24.95 52-week range 52.61
- YTD
- +19.80%
- 1 year
- +62.27%
- Open
- 51.80
- Prev close
- 51.45
- Mkt cap
- 949.34M
- Vol
- 174.41K
- Avg vol
- 260.04K
- EPS
- 16.88
- P/E
- 3.04
- Div yield
- 0.00%
More statistics
- Low
- 50.67
- High
- 52.61
- Forward P/E
- 19.49
- Beta
- 0.95
- Short ratio
- 1.69
- Inst. own
- 68.01%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 20.01
- 200-d avg
- 13.77
- 1y target
- 31.33
Financial health
Altman Z-Score
4.67 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A4 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 4
- P/B 4
Valuation
P/E 2.1×
FY 2016 5y median -4.4× FY 2025
P/S 2.6×
FY 2016 5y median 2.2× FY 2025
P/B 2.0×
FY 2016 5y median 2.0× FY 2025
P/FCF 10.2×
FY 2016 5y median 9.5× FY 2025
EV/EBITDA 6.0×
FY 2016 5y median -5.1× FY 2025
EV/Sales 2.7×
FY 2016 5y median 2.4× FY 2025
FCF Yield 9.8%
FY 2016 5y median 1.2% FY 2025
Profitability
Gross Margin 93.3%
FY 2016 5y median 93.9% FY 2025
Operating Margin 42.6%
FY 2016 5y median -8.4% FY 2025
Net Margin 124.7%
FY 2016 5y median -12.0% FY 2025
ROE 93.8%
FY 2016 5y median 93.8% FY 2025
ROIC 28.2%
FY 2016 5y median -11.0% FY 2025
ROA 71.5%
FY 2016 5y median -10.7% FY 2025
Growth (YoY)
Revenue 64.1%
FY 2016 FY 2025
Operating Income 418.6%
FY 2016 FY 2025
EPS (diluted) 1867.7%
FY 2016 FY 2025
Free Cash Flow 143.5%
FY 2016 FY 2025
Financial Health
Current Ratio 2.4×
FY 2016 5y median 2.1× FY 2025
Quick Ratio 2.3×
FY 2016 5y median 2.0× FY 2025
Debt / Equity 0.1×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA 0.1×
FY 2016 5y median -0.3× FY 2025
Interest Coverage 17.1×
FY 2016 5y median -2.6× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31